For more information about our obstetrics and gynaecology studies, please visit the pages below:

Study Name 




To assess the effect of SHP607 (mecasermin rinfabate) on reducing chronic lung disease (CLD) in preterm infants. This is a phase 2b multicentre, randomised 3 arm study.

Infants born between 23+0 and 27+6 weeks of gestational age

Brain activity 

To understand how the neonatal brain matures and handles information. The brain of a baby -especially if premature - is not just a scaled down version of an adult brain, but has functions that are only present at this early stage of life. Therefore, we need to understand how the brain processes and is affected by the environment around the baby (whether in a positive or negative way). This can help us understand, for example, how neonates perceive pain or how we can better protect brain development.

Most babies over 28 weeks corrected gestational age are eligible to undergo a research brain recording, which is completely safe and painless. Sometimes we time our brain recordings to coincide with a necessary blood test. Occasionally babies require brain recordings for clinical reasons (not for research), and in those instances we may ask permission to use those clinical data for research purposes.

Baby Brain The aim of this study to understand the pathophysiological changes in a developing brain better following neonatal hypoxic ischaemic injury and establish an early biomarker that will help to determine injury severity. All term and preterm babies born at UCH or transferred to UCH for treatment of acute brain injury without life threatening congenital malformations.
Response This study is a phase 1 safety trial of recombinant surfactant protein D to prevent neonatal chronic lung disease. All preterm infants born in UCH at less than 28 weeks gestation, intubated for respiratory distress and stable on the ventilator are eligible.